Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Top Page
Lantern Pharma
(NASDAQ:LTRN)
Select Model
Select Model
Rating:50Neutral
Price Target:
$3.00
▼(-0.66% Downside)
Action:ReiteratedDate:01/23/26
The score is primarily held down by weak financial performance (no revenue, persistent losses, and significant cash burn with a shrinking equity base). Offsetting this, the latest earnings call cited notable clinical/regulatory milestones and AI platform progress, while technicals are neutral-to-slightly positive but not strong enough to outweigh financing and profitability risks.
Positive Factors
Clinical trial validation (LP-184 Phase Ia)
Achieving all primary endpoints with a 48% clinical benefit rate materially de-risks LP-184 relative to early-stage peers. Durable impact: positive human efficacy signals improve prospects for later-stage trials, partnering interest, and regulatory engagement, raising program success probability.
Negative Factors
Pre-revenue with persistent net losses
Remaining pre-revenue means Lantern lacks product-derived cash flow and must fund operations externally. Persistently large net losses imply continued financing dependence, constrain reinvestment capacity, and lengthen the time to sustainable margins or self-funding business model.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical trial validation (LP-184 Phase Ia)
Achieving all primary endpoints with a 48% clinical benefit rate materially de-risks LP-184 relative to early-stage peers. Durable impact: positive human efficacy signals improve prospects for later-stage trials, partnering interest, and regulatory engagement, raising program success probability.
Read all positive factors
Lantern Pharma (LTRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$24.83M
Dividend YieldN/A
Average Volume (3M)45.01K
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue GrowthN/A
EPS Growth1.18%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.39
Shares Outstanding11,184,423
10 Day Avg. Volume40,960
30 Day Avg. Volume45,008
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.62
Price to Sales (P/S)0.00
P/FCF Ratio-1.93
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-276.02
Enterprise Value/Ebitda-0.85
Forecast
1Y Price Target
$25.00Price Target Upside727.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Lantern Pharma Business Overview & Revenue Model
Company Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical tr...
How the Company Makes Money
Lantern Pharma generates revenue primarily through the development and commercialization of its drug candidates. The company uses its proprietary RADR platform to identify biomarkers and genetic signatures that can predict patient response to its ...
Lantern Pharma Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 30, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant achievements in clinical trial results and regulatory progress, along with advancements in AI platform commercialization. Financial stability was noted, but there is a requirement for additional funding in the near future.Positive Updates
Successful LP-184 Phase Ia Clinical Trial
The LP-184 Phase Ia clinical trial successfully achieved all primary endpoints, demonstrating a 48% clinical benefit rate in evaluable cancer patients who received doses at or above the therapeutic threshold.
Negative Updates
Decrease in R&D Expenses
R&D expenses decreased to $2.4 million from $3.7 million year-over-year, primarily due to reductions in research study and materials expenses, consulting, and payroll.
Read all updates
Q3-2025 Updates
Positive
Negative
Successful LP-184 Phase Ia Clinical Trial
The LP-184 Phase Ia clinical trial successfully achieved all primary endpoints, demonstrating a 48% clinical benefit rate in evaluable cancer patients who received doses at or above the therapeutic threshold.
Read all positive updates
Company Guidance
During Lantern Pharma's third quarter 2025 earnings call, the company highlighted several key metrics and milestones, signaling a transformative period. The LP-184 Phase Ia clinical trial achieved all primary endpoints with a 48% clinical benefit rate in cancer patients, particularly those with DNA damage repair mutations. The company also advanced its AI platform, RADR, and outlined future plans for its CNS-focused subsidiary, Starlight Therapeutics. Financially, Lantern reported a net loss of $4.2 million, or $0.39 per share, for the quarter, with $12.4 million in cash and equivalents, providing runway until the third quarter of 2026. The company also discussed its strategic approach to drug development, leveraging AI to identify high-probability success areas, and detailed upcoming clinical trials targeting a combined market opportunity exceeding $7 billion.Lantern Pharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -59.90K | 0.00 | -174.84K | 0.00 | 0.00 | 0.00 |
| EBITDA | -19.41M | -22.20M | -15.79M | -14.42M | -12.58M | -5.90M |
| Net Income | -18.92M | -20.78M | -15.96M | -14.26M | -12.36M | -5.91M |
Balance Sheet | ||||||
| Total Assets | 13.63M | 25.57M | 43.65M | 58.84M | 73.95M | 20.36M |
| Cash, Cash Equivalents and Short-Term Investments | 12.36M | 24.01M | 41.30M | 55.20M | 70.73M | 19.23M |
| Total Debt | 93.95K | 243.66K | 234.47K | 52.89K | 204.95K | 108.50K |
| Total Liabilities | 4.04M | 4.38M | 2.74M | 2.80M | 2.38M | 660.84K |
| Stockholders Equity | 9.59M | 21.19M | 40.91M | 56.04M | 71.57M | 19.70M |
Cash Flow | ||||||
| Free Cash Flow | -16.86M | -17.83M | -14.37M | -12.80M | -10.61M | -5.67M |
| Operating Cash Flow | -16.86M | -17.81M | -14.35M | -12.77M | -10.59M | -5.65M |
| Investing Cash Flow | 16.21M | 3.37M | -930.21K | 179.27K | -19.53M | -16.14K |
| Financing Cash Flow | 971.78K | 66.71K | -500.00K | -2.18M | 63.42M | 23.66M |
Lantern Pharma Technical Analysis
Negative
3.02
Price Trends
2.83
Negative
3.15
Negative
3.59
Negative
Market Momentum
-0.18
Positive
33.33
Neutral
31.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LTRN, the sentiment is Negative. The current price of 3.02 is above the 20-day moving average (MA) of 2.52, above the 50-day MA of 2.83, and below the 200-day MA of 3.59, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 33.33 is Neutral, neither overbought nor oversold. The STOCH value of 31.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LTRN.
Lantern Pharma Risk Analysis
Lantern Pharma disclosed 72 risk factors in its most recent earnings report. Lantern Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Unfavorable geopolitical and macroeconomic developments could adversely affect our business, financial condition or results of operations. Q4, 2023
Lantern Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $40.31M | -4.00 | -146.61% | ― | ― | 37.89% | |
50 Neutral | $24.83M | -2.82 | -125.98% | ― | ― | 1.18% | |
45 Neutral | $20.86M | -0.53 | -143.59% | ― | ― | -53.18% | |
44 Neutral | $11.74M | -0.64 | 780.31% | ― | -100.00% | 32.37% | |
| ― | $89.19M | ― | -3756.61% | ― | ― | 44.50% | |
42 Neutral | $12.62M | ― | -1550.19% | ― | ― | -55.95% |
* Healthcare Sector Average
LTRN
Lantern Pharma
2.22
-1.50
-40.32%
SKYE
Skye Bioscience
0.62
-1.50
-70.57%
BCAB
BioAtla
0.16
-0.23
-59.69%
RNXT
RenovoRx
1.10
0.08
7.84%
MAIA
MAIA Biotechnology, Inc.
1.47
-0.16
-9.82%
MDCX
Medicus Pharma Ltd
0.49
-2.81
-85.06%
Lantern Pharma Corporate Events
Business Operations and StrategyProduct-Related Announcements
Lantern Pharma Showcases AI Platform for Rare Cancers
Positive
Jan 23, 2026
On January 22, 2026, Lantern Pharma hosted an event where it used a prepared presentation to support discussions and a live demonstration of its initial AI tools and multi-agent system designed for rare cancer applications. The event, and the asso...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Lantern Pharma Achieves Key Milestones in Q3 2025
Positive
Nov 13, 2025
Lantern Pharma reported its third quarter 2025 financial results and business updates, highlighting significant progress in clinical validation, regulatory advancements, and strategic momentum. The company achieved all primary endpoints in its LP-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.